Huadong Global Development Center

Huadong Medicine Global Development Center is the international research and clinical development arm of Huadong Medicine, a leading Chinese pharmaceutical company. The center focuses on advancing a diverse pipeline of innovative therapies across oncology, immunology, and metabolic diseases, with a particular emphasis on antibody-drug conjugates (ADCs) and GLP-1 receptor agonists. Operating out of key biotech hubs like Boston and Munich, the center manages global clinical trials and strategic partnerships to bring novel treatments to international markets. Its portfolio includes both internally developed assets and high-profile licensed products, such as the FRα-targeting ADC ELAHERE and the IL-1 inhibitor Arcalyst. The center plays a critical role in the parent company's strategy to transition from a traditional pharmaceutical manufacturer to a global innovation-driven biopharmaceutical leader.